Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland

Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS -mutant Candida albicans / glabrata in Switzerland and provide the microbiological and clinical characterist...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Infection 2020-10, Vol.48 (5), p.761-766
Hauptverfasser:	Coste, A. T., Kritikos, A., Li, J., Khanna, N., Goldenberger, D., Garzoni, C., Zehnder, C., Boggian, K., Neofytos, D., Riat, A., Bachmann, D., Sanglard, D., Lamoth, F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antifungal Agents - therapeutic use Brief Report Candida albicans - drug effects Candida albicans - genetics Candida albicans - physiology Candida glabrata - drug effects Candida glabrata - genetics Candida glabrata - physiology Candidemia - drug therapy Drug Resistance, Fungal Echinocandins - therapeutic use Family Medicine Female General Practice Humans Infectious Diseases Internal Medicine Male Medicine Medicine & Public Health Middle Aged Switzerland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS -mutant Candida albicans / glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15–77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.
ISSN:	0300-8126 1439-0973
DOI:	10.1007/s15010-020-01475-8